Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New Brunswick, New Jersey 08903


RATIONALE: When irradiated donor lymphocytes are infused into the patient they may help the patient's immune system kill tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving irradiated donor lymphocytes works in treating patients with metastatic kidney cancer.

Study summary:

OBJECTIVES: - Determine the response rate in patients with metastatic renal cell carcinoma treated with HLA-partially matched related donor lymphocytes. - Determine the rate and kinetics of clinical/radiological response in patients treated with this regimen. - Determine the toxicity of this regimen in these patients. - Determine the rates of graft-vs-host disease in patients treated with this regimen. OUTLINE: Patients receive irradiated donor lymphocytes IV over 1 hour on day 0. Treatment repeats every 8-16 weeks for up to 6 donor lymphocyte infusions in the absence of disease progression or unacceptable toxicity. Blood is collected periodically for research studies, including immunophenotypic analysis of cells and assay for cytotoxic T-lymphocytes and natural killer-cell activity against target cells. After completion of study treatment, patients are followed for 60 days. PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Diagnosis of clear cell renal cell carcinoma - Metastatic disease - Measurable disease - Previously treated with high-dose aldesleukin OR not eligible for or refused such therapy - No brain metastases by MRI or CT scan - HLA-partially matched (e.g., ≥ 2/6 HLA A, B, Dr match) related donor available - Patients who have no partially matched immediate family member available are eligible if they have a fully HLA-matched donor PATIENT CHARACTERISTICS: - ECOG performance status 0-1 - Bilirubin ≤ 2 times upper limit of normal - Creatinine clearance ≥ 40 mL/min - AST ≤ 3 times ULN - Cardiac ejection fraction ≥ 45% - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: - See Disease Characteristics



Primary Contact:

Principal Investigator
Roger Strair, MD, PhD
Cancer Institute of New Jersey

Backup Contact:


Location Contact:

New Brunswick, New Jersey 08903
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.